Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention

Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention

Background: Prasugrel is recommended over clopidogrel in poor/intermediate CYP2C19 metabolizers with acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), reducing the risk of ischemic events. CYP2C19 genetic testing can guide antiplatelet therapy in ACS patients. Obje...

Full description

Bibliographic Details
Main Authors: Patel V, Lin FJ, Ojo O, Rao S, Yu S, Zhan L, Touchette DR
Format: Article
Language:English
Published: Centro de Investigaciones y Publicaciones Farmaceuticas 2014-09-01
Series:Pharmacy Practice
Subjects:
Clopidogrel
Prasugrel
Acute Coronary Syndrome
Polymorphism Genetic
Genetic Testing
Costs and Cost Analysis
Online Access:http://www.pharmacypractice.org/journal/index.php/pp/article/view/438/359

Internet

http://www.pharmacypractice.org/journal/index.php/pp/article/view/438/359

Similar Items